Staging and Surveillance of Testicular Cancer

Variant: 1 Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.

Procedure	Appropriateness Category	Relative Radiation Level
Radiography chest	Usually Appropriate	☢
MRI abdomen and pelvis without and with IV contrast	Usually Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Appropriate	☢☢☢
MRI abdomen and pelvis without IV contrast	May Be Appropriate	O
MRI head without and with IV contrast	May Be Appropriate	O
CT abdomen and pelvis without IV contrast	May Be Appropriate	☢☢☢
CT chest with IV contrast	May Be Appropriate	☢☢☢
CT chest without IV contrast	May Be Appropriate	☢☢☢
US abdomen and retroperitoneum	Usually Not Appropriate	O
US scrotum	Usually Not Appropriate	O
MRI head without IV contrast	Usually Not Appropriate	O
Bone scan whole body	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT whole body	Usually Not Appropriate	☢☢☢☢

Variant: 2 Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.

Procedure	Appropriateness Category	Relative Radiation Level
Radiography chest	Usually Appropriate	☢
MRI abdomen and pelvis without and with IV contrast	Usually Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Appropriate	☢☢☢
CT chest with IV contrast	Usually Appropriate	☢☢☢
MRI abdomen and pelvis without IV contrast	May Be Appropriate	O
MRI head without and with IV contrast	May Be Appropriate	O
CT abdomen and pelvis without IV contrast	May Be Appropriate	☢☢☢
CT chest without IV contrast	May Be Appropriate	☢☢☢
US abdomen and retroperitoneum	Usually Not Appropriate	O
US scrotum	Usually Not Appropriate	O
MRI head without IV contrast	Usually Not Appropriate	O
Bone scan whole body	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT whole body	Usually Not Appropriate	☢☢☢☢

Variant: 3 Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.

Procedure	Appropriateness Category	Relative Radiation Level
Radiography chest	Usually Appropriate	☢
MRI abdomen and pelvis without and with IV contrast	Usually Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Appropriate	☢☢☢
US scrotum	May Be Appropriate	O
MRI abdomen and pelvis without IV contrast	May Be Appropriate	O
CT abdomen and pelvis without IV contrast	May Be Appropriate	☢☢☢
US abdomen and retroperitoneum	Usually Not Appropriate	O
MRI head without and with IV contrast	Usually Not Appropriate	O
MRI head without IV contrast	Usually Not Appropriate	O
Bone scan whole body	Usually Not Appropriate	☢☢☢
CT chest with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT chest without IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT whole body	Usually Not Appropriate	☢☢☢☢

Variant: 4 Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.

Procedure	Appropriateness Category	Relative Radiation Level
Radiography chest	Usually Appropriate	☢
MRI abdomen and pelvis without and with IV contrast	Usually Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Appropriate	☢☢☢
US scrotum	May Be Appropriate	O
MRI abdomen and pelvis without IV contrast	May Be Appropriate	O
CT abdomen and pelvis without IV contrast	May Be Appropriate	☢☢☢
CT chest with IV contrast	May Be Appropriate	☢☢☢
CT chest without IV contrast	May Be Appropriate	☢☢☢
US abdomen and retroperitoneum	Usually Not Appropriate	O
MRI head without and with IV contrast	Usually Not Appropriate	O
MRI head without IV contrast	Usually Not Appropriate	O
Bone scan whole body	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢
FDG-PET/CT whole body	Usually Not Appropriate	☢☢☢☢

Variant: 5 Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.

Procedure	Appropriateness Category	Relative Radiation Level
Radiography chest	Usually Appropriate	☢
MRI abdomen and pelvis without and with IV contrast	Usually Appropriate	O
CT abdomen and pelvis with IV contrast	Usually Appropriate	☢☢☢
CT chest with IV contrast	Usually Appropriate	☢☢☢
US scrotum	May Be Appropriate	O
MRI abdomen and pelvis without IV contrast	May Be Appropriate	O
MRI head without and with IV contrast	May Be Appropriate	O
CT abdomen and pelvis without IV contrast	May Be Appropriate	☢☢☢
CT chest without IV contrast	May Be Appropriate	☢☢☢
FDG-PET/CT whole body	May Be Appropriate	☢☢☢☢
US abdomen and retroperitoneum	Usually Not Appropriate	O
MRI head without IV contrast	Usually Not Appropriate	O
Bone scan whole body	Usually Not Appropriate	☢☢☢
CT chest without and with IV contrast	Usually Not Appropriate	☢☢☢
CT abdomen and pelvis without and with IV contrast	Usually Not Appropriate	☢☢☢☢

Panel Members

Nicola Schieda, MD^a; Aytekin Oto, MD^b; Brian C. Allen, MD^c; Oguz Akin, MD^d; Samantha J. Barker, MD^e; Pat F. Fulgham, MD^f; Lori Mankowski Gettle, MD, MBA^g; Jodi K. Maranchie, MD^h; Bhavik N. Patel, MD, MBAⁱ; David M. Schuster, MD^j; Dan Smith, MD^k; Baris Turkbey, MD^l; Mark E. Lockhart, MD, MPH^m.

Summary of Literature Review

Introduction/Background

Discussion of Procedures by Variant

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
A. Bone scan whole body

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
B. CT Abdomen and Pelvis

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
C. CT Chest

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
D. FDG-PET/CT Whole Body

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
E. MRI Abdomen and Pelvis

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
F. MRI Head

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
G. Radiography Chest

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
H. US Abdomen and Retroperitoneum

Variant 1: Initial staging of pure seminoma testicular cancer. Diagnosed by orchiectomy.
I. US Scrotum

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
A. Bone scan whole body

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
B. CT Abdomen and Pelvis

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
C. CT Chest

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
D. FDG-PET/CT Whole Body

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
E. MRI Abdomen and Pelvis

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
F. MRI Head

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
G. Radiography Chest

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
H. US Abdomen and Retroperitoneum

Variant 2: Initial staging of nonseminoma testicular cancer. Diagnosed by orchiectomy.
I. US Scrotum

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
A. Bone scan whole body

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
B. CT abdomen and pelvis

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
C. CT Chest

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
D. FDG-PET/CT Whole Body

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
E. MRI Abdomen and Pelvis

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
F. MRI Head

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
G. Radiography Chest

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
H. US Abdomen and Retroperitoneum

Variant 3: Surveillance of stage IA and IB pure seminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
I. US Scrotum

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
A. Bone scan whole body

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
B. CT abdomen and pelvis

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
C. CT Chest

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
D. FDG-PET/CT Whole Body

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
E. MRI Abdomen and Pelvis

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
F. MRI Head

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
G. Radiography Chest

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
H. US Abdomen and Retroperitoneum

Variant 4: Surveillance of stage IA and IB nonseminoma testicular cancer. Diagnosed by orchiectomy. No clinical suspicion of recurrence.
I. US Scrotum

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
A. Bone scan whole body

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
B. CT Abdomen and Pelvis

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
C. CT Chest

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
D. FDG-PET/CT Whole Body

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
E. MRI Abdomen and Pelvis

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
F. MRI Head

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
G. Radiography Chest

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
H. US Abdomen and Retroperitoneum

Variant 5: Surveillance of stage IA and IB pure seminoma and nonseminoma testicular cancer. Diagnosed by orchiectomy. Suspected recurrence.
I. US Scrotum

Summary of Highlights

Supporting Documents

The evidence table, literature search, and appendix for this topic are available at https://acsearch.acr.org/list. The appendix includes the strength of evidence assessment and the final rating round tabulations for each recommendation.

For additional information on the Appropriateness Criteria methodology and other supporting documents, please go to the ACR website at https://www.acr.org/Clinical-Resources/Clinical-Tools-and-Reference/Appropriateness-Criteria.

Appropriateness Category Names and Definitions

Appropriateness Category Name	Appropriateness Rating	Appropriateness Category Definition
Usually Appropriate	7, 8, or 9	The imaging procedure or treatment is indicated in the specified clinical scenarios at a favorable risk-benefit ratio for patients.
May Be Appropriate	4, 5, or 6	The imaging procedure or treatment may be indicated in the specified clinical scenarios as an alternative to imaging procedures or treatments with a more favorable risk-benefit ratio, or the risk-benefit ratio for patients is equivocal.
May Be Appropriate (Disagreement)	5	The individual ratings are too dispersed from the panel median. The different label provides transparency regarding the panel’s recommendation. “May be appropriate” is the rating category and a rating of 5 is assigned.
Usually Not Appropriate	1, 2, or 3	The imaging procedure or treatment is unlikely to be indicated in the specified clinical scenarios, or the risk-benefit ratio for patients is likely to be unfavorable.

Relative Radiation Level Information

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, because of both organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared with those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria^® Radiation Dose Assessment Introduction document.

Relative Radiation Level Designations
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☢	<0.1 mSv	<0.03 mSv
☢☢	0.1-1 mSv	0.03-0.3 mSv
☢☢☢	1-10 mSv	0.3-3 mSv
☢☢☢☢	10-30 mSv	3-10 mSv
☢☢☢☢☢	30-100 mSv	10-30 mSv
*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (e.g., region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as “Varies.”

References

1.	Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021;71:7-33.
2.	Bahrami A, Ro JY, Ayala AG. An overview of testicular germ cell tumors. Arch Pathol Lab Med 2007;131:1267-80.
3.	Brenner H, Gondos A, Arndt V. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol. 2007; 25(22):3274-3280.
4.	Pano B, Sebastia C, Bunesch L, et al. Pathways of lymphatic spread in male urogenital pelvic malignancies. Radiographics. 2011; 31(1):135-160.
5.	Amin MB, Edge S, Greene F, et al. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017.
6.	Hedgire SS, Pargaonkar VK, Elmi A, Harisinghani AM, Harisinghani MG. Pelvic nodal imaging. Radiol Clin North Am 2012;50:1111-25.
7.	Epstein BE, Order SE, Zinreich ES. Staging, treatment, and results in testicular seminoma. A 12-year report. Cancer. 1990; 65(3):405-411.
8.	NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer. Version 3.2020. Available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular.pdf.
9.	Aparicio J, Terrasa J, Duran I, et al. SEOM clinical guidelines for the management of germ cell testicular cancer (2016). Clin Transl Oncol. 18(12):1187-1196, 2016 Dec.
10.	Roth BJ.. Management of Clinical Stage I Germ Cell Tumors. [Review]. Urol Clin North Am. 46(3):353-362, 2019 Aug.
11.	Stephenson A, Eggener SE, Bass EB, et al. Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. J Urol. 202(2):272-281, 2019 08.
12.	Braga FJ, Arbex MA, Haddad J, Maes A. Bone scintigraphy in testicular tumors. Clin Nucl Med. 2001; 26(2):117-118.
13.	Dixon AK, Ellis M, Sikora K. Computed tomography of testicular tumours: distribution of abdominal lymphadenopathy. Clin Radiol. 37(6):519-23, 1986 Nov.
14.	MacVicar D.. Staging of testicular germ cell tumours. [Review] [76 refs]. Clin Radiol. 47(3):149-58, 1993 Mar.
15.	Rowland RG, Weisman D, Williams SD, Einhorn LH, Klatte EC, Donohue JP. Accuracy of preoperative staging in stages A and B nonseminomatous germ cell testis tumors. J Urol. 127(4):718-20, 1982 Apr.
16.	McMahon CJ, Rofsky NM, Pedrosa I. Lymphatic metastases from pelvic tumors: anatomic classification, characterization, and staging. [Review] [98 refs]. Radiology. 254(1):31-46, 2010 Jan.
17.	Hilton S, Herr HW, Teitcher JB, Begg CB, Castellino RA. CT detection of retroperitoneal lymph node metastases in patients with clinical stage I testicular nonseminomatous germ cell cancer: assessment of size and distribution criteria. AJR Am J Roentgenol. 169(2):521-5, 1997 Aug.
18.	Husband JE, Barrett A, Peckham MJ. Evaluation of computed tomography in the management of testicular teratoma. Br J Urol. 53(2):179-83, 1981 Apr.
19.	Jing B, Wallace S, Zornoza J. Metastases to retroperitoneal and pelvic lymph nodes: computed tomography and lymphangiography. [Review] [61 refs]. Radiol Clin North Am. 20(3):511-30, 1982 Sep.
20.	Richie JP, Garnick MB, Finberg H. Computerized tomography: how accurate for abdominal staging of testis tumors?. J Urol. 127(4):715-7, 1982 Apr.
21.	Strohmeyer T, Geiser M, Ackermann R, Mumperow E, Hartmann M. Value of computed tomography in the staging of testicular tumors. Urol Int. 1988; 43(4):198-200.
22.	Thomas JL, Bernardino ME, Bracken RB. Staging of testicular carcinoma: comparison of CT and lymphangiography. AJR Am J Roentgenol. 137(5):991-6, 1981 Nov.
23.	Hansen J, Jurik AG. Diagnostic value of multislice computed tomography and magnetic resonance imaging in the diagnosis of retroperitoneal spread of testicular cancer: a literature review. [Review] [64 refs]. Acta Radiol. 50(9):1064-70, 2009 Nov.
24.	Hudolin T, Kastelan Z, Knezevic N, Goluza E, Tomas D, Coric M. Correlation between retroperitoneal lymph node size and presence of metastases in nonseminomatous germ cell tumors. Int J Surg Pathol. 20(1):15-8, 2012 Feb.
25.	Coursey Moreno C, Small WC, Camacho JC, et al. Testicular tumors: what radiologists need to know--differential diagnosis, staging, and management. Radiographics. 35(2):400-15, 2015 Mar-Apr.
26.	Howard SA, Gray KP, O'Donnell EK, Fennessy FM, Beard CJ, Sweeney CJ. Craniocaudal retroperitoneal node length as a risk factor for relapse from clinical stage I testicular germ cell tumor. AJR Am J Roentgenol. 203(4):W415-20, 2014 Oct.
27.	Maakaron JE, Gasparis PT, Althouse S, et al. Three-dimensional lymph node volume and craniocaudal lymph node length as an independent risk factor for recurrence or presence of micrometastatis in clinical stage I non-seminomatous germ cell tumors: A retrospective study. J Clin Oncol 2015;33:e15547-e47.
28.	Ozturk C, Velleman T, Bongaerts AH, et al. Assessment of Volumetric versus Manual Measurement in Disseminated Testicular Cancer; No Difference in Assessment between Non-Radiologists and Genitourinary Radiologist. PLoS ONE [Electronic Resource]. 12(1):e0168977, 2017.
29.	Einstein DM, Singer AA, Chilcote WA, Desai RK. Abdominal lymphadenopathy: spectrum of CT findings. Radiographics. 11(3):457-72, 1991 May.
30.	Harvey ML, Geldart TR, Duell R, Mead GM, Tung K. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer--a necessary risk?. Ann Oncol. 13(2):237-42, 2002 Feb.
31.	Meyer CA, Conces DJ. Imaging of intrathoracic metastases of nonseminomatous germ cell tumors. Chest Surg Clin N Am. 2002; 12(4):717-738.
32.	Horan G, Rafique A, Robson J, Dixon AK, Williams MV. CT of the chest can hinder the management of seminoma of the testis; it detects irrelevant abnormalities. Br J Cancer 2007;96:882-5.
33.	Cascade PN, Gross BH, Kazerooni EA, et al. Variability in the detection of enlarged mediastinal lymph nodes in staging lung cancer: a comparison of contrast-enhanced and unenhanced CT. AJR Am J Roentgenol. 170(4):927-31, 1998 Apr.
34.	Cremerius U, Effert PJ, Adam G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998; 39(5):815-822.
35.	Cremerius U, Wildberger JE, Borchers H, et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer?--Results of a study in 50 patients. Urology. 1999; 54(5):900-904.
36.	de Wit M, Brenner W, Hartmann M, et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann Oncol. 2008; 19(9):1619-1623.
37.	Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med. 2000; 27(5):590-594.
38.	Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur J Nucl Med Mol Imaging. 2003; 30(3):396-402.
39.	Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002; 89(6):549-556.
40.	NCCN Clinical Practice Guidelines in Oncology. Testicular Cancer. NCCN Evidence Blocks. Version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/testicular_blocks.pdf.
41.	Ellis JH, Bies JR, Kopecky KK, Klatte EC, Rowland RG, Donohue JP. Comparison of NMR and CT imaging in the evaluation of metastatic retroperitoneal lymphadenopathy from testicular carcinoma. J Comput Assist Tomogr. 8(4):709-19, 1984 Aug.
42.	Glazer HS, Lee JK, Levitt RG, et al. Radiation fibrosis: differentiation from recurrent tumor by MR imaging. Radiology. 1985; 156(3):721-726.
43.	Hogeboom WR, Hoekstra HJ, Mooyaart EL, et al. The role of magnetic resonance imaging and computed tomography in the treatment evaluation of retroperitoneal lymph-node metastases of non-seminomatous testicular tumors. Eur J Radiol. 1991; 13(1):31-36.
44.	Harisinghani MG, Saksena M, Ross RW, et al. A pilot study of lymphotrophic nanoparticle-enhanced magnetic resonance imaging technique in early stage testicular cancer: a new method for noninvasive lymph node evaluation. Urology. 2005; 66(5):1066-1071.
45.	Sohaib SA, Koh DM, Barbachano Y, et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol. 2009; 64(4):362-367.
46.	Rud E, Langberg CW, Baco E, Lauritzen P, Sandbaek G. MRI in the Follow-up of Testicular Cancer: Less is More. Anticancer Research. 39(6):2963-2968, 2019 Jun.
47.	Laukka M, Mannisto S, Beule A, Kouri M, Blomqvist C. Comparison between CT and MRI in detection of metastasis of the retroperitoneum in testicular germ cell tumors: a prospective trial. Acta Oncologica. 59(6):660-665, 2020 Jun.
48.	Fernandez EB, Colon E, McLeod DG, Moul JW. Efficacy of radiographic chest imaging in patients with testicular cancer. Urology. 1994; 44(2):243-248; discussion 248-249.
49.	Steinfeld AD, Macher MS. Radiologic staging of chest in testicular seminoma. Urology. 1990; 36(5):428-430.
50.	Mao Y, Hedgire S, Harisinghani M. Radiologic Assessment of Lymph Nodes in Oncologic Patients. Current Radiology Reports 2013;2.
51.	See WA, Hoxie L. Chest staging in testis cancer patients: imaging modality selection based upon risk assessment as determined by abdominal computerized tomography scan results. J Urol. 1993; 150(3):874-878.
52.	Huddart RA, O'Doherty MJ, Padhani A, et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22--the NCRI Testis Tumour Clinical Study Group. J Clin Oncol. 2007; 25(21):3090-3095.
53.	Sohaib SA, Koh DM, Husband JE. The role of imaging in the diagnosis, staging, and management of testicular cancer. [Review] [45 refs]. AJR Am J Roentgenol. 191(2):387-95, 2008 Aug.
54.	White PM, Adamson DJ, Howard GC, Wright AR. Imaging of the thorax in the management of germ cell testicular tumours. Clin Radiol. 1999; 54(4):207-211.
55.	Sadow CA, Maurer AN, Prevedello LM, Sweeney CJ, Silverman SG. CT restaging of testicular germ cell tumors: The incidence of isolated pelvic metastases. European Journal of Radiology. 85(8):1439-44, 2016 Aug.
56.	Rustin GJ, Mead GM, Stenning SP, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197--the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007;25:1310-5.
57.	De La Pena H, Sharma A, Glicksman C, et al. No longer any role for routine follow-up chest x-rays in men with stage I germ cell cancer. Eur J Cancer. 84:354-359, 2017 10.
58.	Kollmannsberger C, Tandstad T, Bedard PL, et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 2015;33:51-7.
59.	Tolan S, Vesprini D, Jewett MA, et al. No role for routine chest radiography in stage I seminoma surveillance. Eur Urol 2010;57:474-9.
60.	American College of Radiology. ACR Appropriateness Criteria® Radiation Dose Assessment Introduction. Available at: https://edge.sitecorecloud.io/americancoldf5f-acrorgf92a-productioncb02-3650/media/ACR/Files/Clinical/Appropriateness-Criteria/ACR-Appropriateness-Criteria-Radiation-Dose-Assessment-Introduction.pdf.

Disclaimer

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient’s clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient’s condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.